This Article Full Text Full Text (PDF) All Versions of this Article: 52/1/150    most recent HYPERTENSIONAHA.107.104158v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Gauthier, K. M. Articles by Campbell, W. B. PubMed PubMed Citation Articles by Gauthier, K. M. Articles by Campbell, W. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LOSARTAN POTASSIUM NITRIC OXIDE Related Collections Biochemistry and metabolism ACE/Angiotension receptors Hypertension - basic studies Endothelium/vascular type/nitric oxide

(Hypertension. 2008;52:150.)
© 2008 American Heart Association, Inc.

Original Articles

Angiotensin II Relaxations of Bovine Adrenal Cortical Arteries

Role of Angiotensin II Metabolites and Endothelial Nitric Oxide

Kathryn M. Gauthier; David X. Zhang; Lijie Cui; Kasem Nithipatikom; William B. Campbell

From the Department of Pharmacology and Toxicology (K.M.G., L.C., K.N., W.B.C.) and Internal Medicine and Cardiovascular Center (D.X.Z.), Medical College of Wisconsin, Milwaukee.

Correspondence to Kathryn M. Gauthier, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail kgauth{at}mcw.edu

Angiotensin (Ang) II regulates adrenal steroidogenesis and adrenal cortical arterial tone. Vascular metabolism could decrease Ang II concentrations and produce metabolites with vascular activity. Our goals were to study adrenal artery Ang II metabolism and to characterize metabolite vascular activity. Bovine adrenal cortical arteries were incubated with Ang II (100 nmol/L) for 10 and 30 minutes. Metabolites were analyzed by mass spectrometry. Ang (1-7), Ang III, and Ang IV concentrations were 146±21, 173±42 and 58±11 pg/mg at 10 minutes and 845±163, 70±14, and 31±3 pg/mg at 30 minutes, respectively. Concentration-related relaxations of U46619-preconstricted cortical arteries to Ang II (maximum relaxation=29±3%; EC₅₀=3.4 pmol/L) were eliminated by endothelium removal and inhibited by the NO synthase inhibitor, nitro-L-arginine (30 µmol/L; maximum relaxation=14±7%). Ang II relaxations were enhanced by the angiotensin type-1 receptor antagonist losartan (1 µmol/L; maximum relaxation=41±3%; EC₅₀=11 pmol/L). Losartan-enhanced Ang II relaxations were inhibited by nitro-L-arginine (maximum relaxation=18±5%) and the angiotensin type-2 receptor antagonist PD123319 (10 µmol/L; maximum relaxation=27±5%). Ang (1-7) and Ang III caused concentration-related relaxations with less potency (EC₅₀=43 and 24 nmol/L, respectively) but similar efficacy (maximum relaxations=39±3% and 48±5%, respectively) as losartan-enhanced Ang II relaxations. Ang (1-7) relaxations were inhibited by nitro-L-arginine (maximum relaxation=16±4%) and the Ang (1-7) receptor antagonist 7^D-Ala-Ang (1-7) (1 µmol/L; maximum relaxation=10±3%) and eliminated by endothelium removal. Thus, Ang II metabolism by adrenal cortical arteries to metabolites with decreased vascular activity represents an inactivation pathway possibly decreasing Ang II presentation to adrenal steroidogenic cells and limits Ang II vascular effects.

Key Words: angiotensin (1-7) • angiotensin III • angiotensin IV • mass spectrometry